REGULATORY

LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation

July 3, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Four heavyweight members of the ruling Liberal Democratic Party (LDP) have set up a private study group to discuss ways for bolstering Japan’s drug discovery infrastructure, Jiho has learned. The four members are former LDP secretary general Akira Amari, former…

To read the full story

Study Group of LDP Heavyweights Eyes “Drug Discovery Agency”
August 7, 2023

REGULATORY

METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Health Insurance Reform Bill Sails Through Lower House
April 30, 2026
MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…